Abstract

Endometriosis represents a significant health problem for women of reproductive age. Defined as the presence of endometrial-like glands and stroma in any extrauterine site, endometriosis continues to defy our complete understanding regarding etiology, the relationship between extent of disease and the degree of symptoms, its relationship to fertility, and the most appropriate means of therapy. The purpose of this document is to present the evidence, including risks and benefits, for the effectiveness of medical therapy for women who experience symptoms and problems believed to be secondary to endometriosis.

Highlights

  • Endometriosis is a chronic and benign gynecological disorder affecting women of reproductive age group

  • These major drawbacks of current treatments often lead to abandonment of medical therapy and calls for repeated surgical therapy

  • As with gonadotropin releasing hormone (GnRH) agonists, the primary concern with progestin use is the potential loss of BMD. The efficacy of both treatment regimens is comparable in relieving pain symptoms, studies have shown that GnRH agonists have persistent as well as higher degree of BMD loss

Read more

Summary

Introduction

Endometriosis is a chronic and benign gynecological disorder affecting women of reproductive age group. It is characterized by the presence of endometrial gland and stromal tissue outside the uterine cavity, primarily within pelvic cavity. This chronic disease has a negative impact on the quality of life of women by causing symptoms like chronic pelvic pain, severe dysmenorrhoea, dyspareunia and infertility. Current medical treatment regimes rely on the fact that endometriosis is an estrogen-dependent disease and are limited to hormonal drugs that suppress the menstrual cycle and activity of endometriotic lesions, aiming to relieve pain and bleeding. Relief is at the cost of adverse effects of these drugs like induction of a hypo-estrogenic state, which

Conventional treatment modalities
Findings
Dienogest – a novel progestin for long term treatment of endometriosis

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.